Salarius Pharmaceuticals, Inc. Board of Directors

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.

Mr. David J. Arthur M.B.A.

Mr. David J. Arthur M.B.A.

CEO, President & Director

Mr. Mark J. Rosenblum CPA

Mr. Mark J. Rosenblum CPA

Executive VP of Finance & CFO

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.